Document Detail

Hemodynamic effects of cadralazine in hexamethonium treated and non-treated anesthetized dogs.
MedLine Citation:
PMID:  3382459     Owner:  NLM     Status:  MEDLINE    
Hemodynamic effects of the newly synthesized vasodilator cadralazine (ethyl(+/)-6-[ethyl(2-hydroxypropyl)amino]-3- pyridazinecarbazate) were compared with those of hydralazine and budralazine in hexamethonium treated and non-treated anesthetized dogs. In hexamethonium non-treated dogs, cadralazine (1 and 3 mg/kg i.v.) exerted a dose-dependent and sustained decrease in systolic and diastolic arterial blood pressure similar to that of budralazine (10 mg/kg i.v.) and the effect was slow in onset and long lasting until 5 h after administration compared with hydralazine (0.5 and 1 mg/kg i.v.). Total peripheral vascular resistance was decreased by these three drugs. The common carotid, femoral and renal arterial blood flow increased as a result of the decrease in vascular resistance, but the superior mesenteric arterial flow has not significantly changed. Blood flow increase in the renal artery was fast and that in the femoral artery was predominant. Treatment with hexamethonium decreased blood pressure, but cadralazine caused a further decrease within 60 min similarly to the decrease pattern of hydralazine. Common carotid and femoral arterial vascular resistance also decreased by hexamethonium treatment and a further decrease was observed by administration of cadralazine. Heart rate and cardiac output were immediately and significantly increased by cadralazine, but the increment in heart rate was diminished by the treatment with hexamethonium. Therefore the tachycardiac response is assumed to be caused by baroreceptor reflex and compensates the decrease in vascular resistance which results in moderation of manifestation of the early stage hypotensive effect of cadralazine.
T Higashio; Y Tsuji; K Nakao; S Sakaguchi; M Tanaka
Related Documents :
7455399 - Control of breathing during acute hemorrhage in anesthetized cats.
21958929 - Comparison of manually triggered ventilation and bag-valve-mask ventilation during card...
17449549 - Analysis of complex flow and the relationship between blood pressure, wall shear stress...
1849369 - Postexcitatory depression of baroreceptors in dogs with experimental heart failure.
6880809 - Prostaglandin-mediated inhibition of noradrenaline release. vii. effect of indomethacin...
12923399 - Pulse pressure is independently associated with carotid plaque ulceration.
9989099 - The management of variceal bleeding: past, present and future.
15297829 - Activation of fibrinolytic pathways is associated with duration of supraceliac aortic c...
8262089 - Ischaemia induced alternans of action potential duration in the intact-heart: dependenc...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Arzneimittel-Forschung     Volume:  38     ISSN:  0004-4172     ISO Abbreviation:  Arzneimittelforschung     Publication Date:  1988 Mar 
Date Detail:
Created Date:  1988-07-20     Completed Date:  1988-07-20     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  0372660     Medline TA:  Arzneimittelforschung     Country:  GERMANY, WEST    
Other Details:
Languages:  eng     Pagination:  350-8     Citation Subset:  IM    
Research and Development Subdivision, Ciba-Geigy Limited, Hyogo, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Blood Pressure / drug effects
Cardiac Output / drug effects
Ganglia, Autonomic / drug effects
Heart Rate / drug effects
Hemodynamics / drug effects*
Hexamethonium Compounds / pharmacology*
Pyridazines / pharmacology*
Regional Blood Flow / drug effects
Stroke Volume / drug effects
Vascular Resistance / drug effects
Reg. No./Substance:
0/Hexamethonium Compounds; 0/Pyridazines; 64241-34-5/cadralazine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Effects of cadralazine on contractions induced by Ca2+ and norepinephrine in isolated rabbit aortic ...
Next Document:  Pharmacokinetics of 4-oxa-5-exo-(N-methylcarbamoyloxy)-tricyclo- [ 2,6-endo] dec-8-en-3-one ...